Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome

    Suna Özdemir, Hüseyin Görkemli, Kazım Gezginç, Mustafa Özdemir, Aysel Kıyıcı
    TLDR MPA improved hormonal imbalances and acne in women with PCOS without affecting metabolism.
    The study investigated the effects of medroxyprogesterone acetate (MPA) and ethinyl estradiol plus drospirenone on women with polycystic ovary syndrome (PCOS) over 6 months, involving 63 participants. MPA treatment resulted in significant decreases in luteinizing hormone, total testosterone, free androgen index, acne, and seborrhea scores, without affecting lipid or carbohydrate metabolism. In contrast, the ethinyl estradiol plus drospirenone group experienced increases in lipid and hormone values, while acne, seborrhea, hair loss, and Ferriman-Gallwey scores decreased. Both treatments did not significantly alter the total cholesterol to high-density cholesterol ratio. MPA was effective in controlling menstrual cycles and improving hormonal imbalances related to hyperandrogenism.
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results

    Related Research

    5 / 5 results